Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InnoCan PharmaHAM:IP40 -4.46%56 Debt-to-Equity is 0.27 as of Mar. 2026, which is 2600% above its 10-year median of 0.01. GuruFocus rates HAM:IP40 with a GF Score™ of 56/100 and a GF Value™ of €9.78 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 1,745 Consumer Packaged Goods companies, InnoCan Pharma ranks better than 61.49% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for InnoCan Pharma's Debt-to-Equity or its related term are showing as below:
HAM:IP40'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.01 Med: 0.01 Max: 0.64
Current: 0.27
During the past 8 years, the highest Debt-to-Equity Ratio of InnoCan Pharma was 0.64. The lowest was -0.01. And the median was 0.01.
HAM:IP40's Debt-to-Equity is ranked better than 61.49% of 1745
companies
in the Consumer Packaged Goods industry
Industry Median: 0.41
vs HAM:IP40: 0.27
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
InnoCan Pharma Debt-to-Equity Related Terms
InnoCan Pharma Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for InnoCan Pharma's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:IP40 vs PG, CL, KVUE: Debt-to-Equity Comparison
For the Household & Personal Products subindustry, InnoCan Pharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InnoCan Pharma Debt-to-Equity vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, InnoCan Pharma's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where InnoCan Pharma's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InnoCan Pharma (HAM:IP40) has a Debt-to-Equity of 0.27 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on InnoCan Pharma and its competitors. This is 2600% above median its historical median of 0.01. According to the industry distribution chart, InnoCan Pharma ranks #672 out of 1745 companies in the Consumer Packaged Goods industry, placing it in the top 38.5%.
Is InnoCan Pharma's Debt-to-Equity too high?
InnoCan Pharma's current Debt-to-Equity of 0.27 is 2600% above median its 10-year median of 0.01. The Consumer Packaged Goods industry median Debt-to-Equity is 0.41. InnoCan Pharma's value of 0.27 is 34.1% below this industry median. Based on the distribution chart, InnoCan Pharma ranks #672 out of 1745 companies in the Consumer Packaged Goods industry, which is above the industry midpoint. Overall, InnoCan Pharma has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InnoCan Pharma's Debt-to-Equity compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, InnoCan Pharma ranks #672 out of 1745 companies for Debt-to-Equity. This puts InnoCan Pharma in the upper half of its industry. The industry median Debt-to-Equity is 0.41. InnoCan Pharma's value of 0.27 is 34.1% below this benchmark. While the company's 10-year median is 0.01 vs. the industry median of 0.41, InnoCan Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Consumer Packaged Goods company?
The median Debt-to-Equity among Consumer Packaged Goods companies is 0.41, based on 1,745 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. InnoCan Pharma's current Debt-to-Equity of 0.27 is 34.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on InnoCan Pharma and its competitors. For the Consumer Packaged Goods industry, the median Debt-to-Equity is 0.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InnoCan Pharma's current Debt-to-Equity is 0.27, which is 2600% above median its own 10-year median of 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCan Pharma stock overvalued right now?
Based on GuruFocus' analysis, InnoCan Pharma (HAM:IP40) is currently considered Possible Value Trap. The stock's GF Value™ is €9.78, compared to a current price of €1.72 — trading 82.5% below its estimated fair value. The current Debt-to-Equity is 0.27, which is 2600% above median its 10-year median of 0.01 and 34.1% below the Consumer Packaged Goods industry median of 0.41. InnoCan Pharma's overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For InnoCan Pharma (HAM:IP40), the current Debt-to-Equity is 0.27 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InnoCan Pharma (HAM:IP40) Overvalued in 2026?
Based on GuruFocus' analysis, InnoCan Pharma stock appears to be undervalued.
The current stock price of €1.72 is trading 82.5% below its estimated GF Value™ of €9.78.
GuruFocus considers InnoCan Pharma to be Possible Value Trap.
Key valuation signals for HAM:IP40:
Debt-to-Equity: 0.27 (2600% above median its 10-year median of 0.01)
GF Value™: €9.78 vs. price of €1.72 (82.5% below fair value)
Industry Position: 34.1% below the Consumer Packaged Goods median (#672 of 1745)
No single metric tells the full story. See the HAM:IP40 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InnoCan Pharma Corp develops consumer wellness and pharmaceutical products. It has developed a preclinical-stage Cannabidiol-loaded Liposome injection Platform (CBD-LPT) for non-opioid pain management, and is involved in developing and marketing various self-care and CBD beauty products. Additionally, the Group offers cosmetic products such as anti-aging beauty sleeping masks, anti-puffiness eye serum, anti-aging facial serum, hair cream, etc., which are sold mainly through online marketplaces. Its operating segments are: Online sales and Other operations. The majority of its revenue is generated from the Online sales segment, which engages in the development, manufacture, and marketing of cosmetic products. Geographically, the Group generates maximum revenue from the United States.
56GF Score
Get the complete analysis for HAM:IP40
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:IP40 has been successfully added to your 
